AU2005320352A8 - Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer - Google Patents

Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Download PDF

Info

Publication number
AU2005320352A8
AU2005320352A8 AU2005320352A AU2005320352A AU2005320352A8 AU 2005320352 A8 AU2005320352 A8 AU 2005320352A8 AU 2005320352 A AU2005320352 A AU 2005320352A AU 2005320352 A AU2005320352 A AU 2005320352A AU 2005320352 A8 AU2005320352 A8 AU 2005320352A8
Authority
AU
Australia
Prior art keywords
lung cancer
kit
detecting
pea
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005320352A
Other versions
AU2005320352A2 (en
AU2005320352A1 (en
Inventor
Pinchas Akiva
Michal Ayalon-Soffer
Gad S. Cojocaru
Dvir Dahary
Alexander Diber
Naomi Keren
Zurit Levine
Amit Novik
Sarah Pollock
Shirley Sameah-Greenwald
Osnat Sella-Tavor
Ronen Shemesh
Rotem Sorek
Amir Toporik
Shira Walach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compugen USA Inc
Original Assignee
Compugen USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen USA Inc filed Critical Compugen USA Inc
Priority claimed from US11/051,720 external-priority patent/US7569662B2/en
Publication of AU2005320352A2 publication Critical patent/AU2005320352A2/en
Publication of AU2005320352A1 publication Critical patent/AU2005320352A1/en
Publication of AU2005320352A8 publication Critical patent/AU2005320352A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Description

Patents Office File reference: 2005320352 Subject: Editorial Note The description for this application was filed on CD and can be viewed by contacting IP Australia 10 August 2006 Document Page 1 of 1

Claims (22)

1. An isolated polynucleotide comprising a polynucleotide having a sequence of RI 1723_PEA_1_T5.
2. The isolated polynucleotide of claim 1, comprising a node having a sequence of: Rl1723_PEA_1 node_13.
3. An isolated polypeptide comprising a polypeptide having a sequence of: RI 1723 PEA 1 P13.
4. The isolated of claim 3, comprising a chimeric polypeptide encoding for RI 1723_PEA_1_P13, comprising a first amino acid sequence being at least 95 % homologous to MWVLGIAATFCGLFLLPGFALQIQCYQCEEFQLNNDCSSPEFIVNCTVNVQDMCQKEV MEQSA corresponding to amino acids 1 - 63 of Q96AC2, which also corresponds to amino acids 1 - 63 of RI 1723_PEA_1_P13, and a second amino acid sequence being at least about 95% homologous to a polypeptide having the sequence DTKRTNTLLFEMRHFAKQLTT corresponding to amino acids 64 - 84 of RI 1723_PEA_1_P13, wherein said first and second amino acid sequences are contiguous and in a sequential order. 4. The isolated polypeptide of claim 4, comprising a tail of RI 1723_PEA_1_P13, comprising a polypeptide being at least about 95% homologous to the sequence DTKRTNTLLFEMRHFAKQLTT in RI 1723_PEA_1_P13.
5. The isolated oligonucleotide of claim 1, comprising an amplicon according to SEQ ID NO: 1684.
6. A primer pair, comprising a pair of isolated oligonucleotides capable of amplifying said amplicon of claim 5. 1402
7. The primer pair of claim 6, comprising a pair of isolated oligonucleotides: SEQ NOs 1682 and 1683.
8. An antibody capable of specifically binding to an epitope of an amino acid sequence of claim 3.
9. The antibody of claim 8, wherein said amino acid sequence comprises said tail of claim 4.
10. The antibody of claim 8, wherein said antibody is capable of differentiating between a splice variant having said epitope and a corresponding known protein PSEC.
11. A kit for detecting lung cancer, comprising a kit detecting overexpression of a splice variant according to claim 1.
12. The kit of claim 11, wherein said kit comprises a NAT-based technology.
13. The kit of claim 11, wherein said kit further comprises at least one primer pair capable of selectively hybridizing to a nucleic acid sequence according to claim 1.
14. The kit of claim 11, wherein said kit further comprises at least one oligonucleotide capable of selectively hybridizing to a nucleic acid sequence according to claim 1. 12. A kit for detecting lung cancer, comprising a kit detecting overexpression of a splice variant according to claim 3, said kit comprising an antibody according claim 8. 13. The kit of claim 12, wherein said kit further comprises at least one reagent for performing an ELISA or a Western blot. 1403 14. A method for detecting lung cancer, comprising detecting overexpression of a splice variant according to claim 1.
15. The method of claim 14, wherein said detecting overexpression is performed with a NAT-based technology.
16. A method for detecting lung cancer, comprising detecting overexpression of a splice variant according to claim 3, wherein said detecting overexpression is performed with an immunoassay.
17. The method of claim 16, wherein said immunoassay comprises an antibody according to claim 8.
18. A biomarker capable of detecting lung cancer, comprising a nucleic acid sequence according to claim 1 or a fragment thereof, or an amino acid sequence according to claim 3 or a fragment thereof.
19. A method for screening for lung cancer, comprising detecting lung cancer cells with a biomarker according to claim 18.
20. A method for diagnosing lung cancer, comprising detecting lung cancer cells with a biomarker according to claim 18.
21. A method for monitoring disease progression and/or treatment efficacy and/or relapse of lung cancer, comprising detecting lung cancer cells with a biomarker according to claim 18.
22. A method of selecting a therapy for lung cancer, comprising detecting lung cancer cells with a biomarker according to claim 18 and selecting a therapy according to said detection.
AU2005320352A 2004-01-27 2005-01-27 Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer Abandoned AU2005320352A1 (en)

Applications Claiming Priority (63)

Application Number Priority Date Filing Date Title
US53912804P 2004-01-27 2004-01-27
US53912904P 2004-01-27 2004-01-27
US60/539,128 2004-01-27
US60/539,129 2004-01-27
US58981504P 2004-07-22 2004-07-22
US60/589,815 2004-07-22
US60730704P 2004-09-07 2004-09-07
US60/607,307 2004-09-07
US62091804P 2004-10-22 2004-10-22
US62092404P 2004-10-22 2004-10-22
US62097404P 2004-10-22 2004-10-22
US62065604P 2004-10-22 2004-10-22
US62067704P 2004-10-22 2004-10-22
US62091704P 2004-10-22 2004-10-22
US62097504P 2004-10-22 2004-10-22
US62100404P 2004-10-22 2004-10-22
US62085304P 2004-10-22 2004-10-22
US62086804P 2004-10-22 2004-10-22
US62087404P 2004-10-22 2004-10-22
US62091604P 2004-10-22 2004-10-22
US60/620,917 2004-10-22
US60/620,868 2004-10-22
US60/620975 2004-10-22
US60/620,924 2004-10-22
US60/620,853 2004-10-22
US60/620,677 2004-10-22
US60/620,918 2004-10-22
US60/620,906 2004-10-22
US60/620,874 2004-10-22
US60/620,656 2004-10-22
US60/621,004 2004-10-22
US60/620,974 2004-10-22
US62105304P 2004-10-25 2004-10-25
US62113104P 2004-10-25 2004-10-25
US60/621,053 2004-10-25
US60/621,131 2004-10-25
US62814504P 2004-11-17 2004-11-17
US62811204P 2004-11-17 2004-11-17
US62811104P 2004-11-17 2004-11-17
US62818904P 2004-11-17 2004-11-17
US62815604P 2004-11-17 2004-11-17
US62810104P 2004-11-17 2004-11-17
US62813404P 2004-11-17 2004-11-17
US62812304P 2004-11-17 2004-11-17
US62817804P 2004-11-17 2004-11-17
US62816704P 2004-11-17 2004-11-17
US62825104P 2004-11-17 2004-11-17
US60/628,167 2004-11-17
US60/628,111 2004-11-17
US60/628,251 2004-11-17
US60/628,134 2004-11-17
US60/628,178 2004-11-17
US60/628,101 2004-11-17
US60/628,156 2004-11-17
US60/628112 2004-11-17
US60/628,189 2004-11-17
US60/628,145 2004-11-17
US60/628,123 2004-11-17
US63407504P 2004-12-08 2004-12-08
US60/634,075 2004-12-08
US11/051,720 US7569662B2 (en) 2004-01-27 2005-01-27 Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US11/051,720 2005-01-27
PCT/IB2005/004037 WO2006131783A2 (en) 2004-01-27 2005-01-27 Polynucleotides, polypeptides, and diagnosing lung cancer

Publications (3)

Publication Number Publication Date
AU2005320352A2 AU2005320352A2 (en) 2006-08-31
AU2005320352A1 AU2005320352A1 (en) 2006-08-31
AU2005320352A8 true AU2005320352A8 (en) 2009-04-30

Family

ID=37450522

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005320352A Abandoned AU2005320352A1 (en) 2004-01-27 2005-01-27 Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer

Country Status (5)

Country Link
EP (1) EP1774046A4 (en)
JP (1) JP2008507261A (en)
AU (1) AU2005320352A1 (en)
CA (1) CA2555509A1 (en)
WO (1) WO2006131783A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008522632A (en) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド Polynucleotide and polypeptide sequences involved in the process of bone remodeling
BRPI0917592B1 (en) 2008-12-09 2021-08-17 Genentech, Inc ANTI-PD-L1 ANTIBODY, COMPOSITION, MANUFACTURED ARTICLES AND USES OF A COMPOSITION
KR101403019B1 (en) 2013-02-25 2014-06-03 서울대학교산학협력단 Novel biomarker for the diagnosis of lung cancer
CN114804550B (en) * 2022-06-10 2023-06-02 安徽新宇环保科技股份有限公司 Sewage treatment regulation and control system based on neural network model
CN115894942B (en) * 2022-11-07 2024-01-12 同济大学 Hyperbranched comb-type polylysine modified by polycaprolactone and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE243938T1 (en) * 1997-08-14 2003-07-15 Novozymes As ANTIMICROBIAL COMPOSITION CONTAINING HALOPEROXIDASE AND SOURCES OF HYDROGEN PEROXIDE, HALOGENE AND AMMONIA
US20030170255A1 (en) * 1999-06-30 2003-09-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2002004514A2 (en) * 2000-07-11 2002-01-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CA2444691A1 (en) * 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003234623A1 (en) * 2002-05-16 2003-12-02 Euro-Celtique, S.A. Use of gastrin releasing peptide (grp) and its receptor in cancer screening

Also Published As

Publication number Publication date
EP1774046A2 (en) 2007-04-18
WO2006131783A3 (en) 2009-08-27
AU2005320352A2 (en) 2006-08-31
WO2006131783A2 (en) 2006-12-14
CA2555509A1 (en) 2005-07-27
EP1774046A4 (en) 2010-09-15
JP2008507261A (en) 2008-03-13
AU2005320352A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
Olsen et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes
JP2005522999A5 (en)
EP2154245A3 (en) Composition and method for diagnosing kidney cancer and for predicting prognosis for kidney cancer patient
CA2712079A1 (en) Compositions and methods of detecting post-stop peptides
AU2005320352A8 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
JP2003501038A5 (en)
JP2010259438A5 (en)
CA2139070A1 (en) Method for enhancing detection ability of nucleic acid assays employing polymerase chain reaction
RU2009135270A (en) METHODS FOR DETECTING AN INFLAMMATORY INTESTINAL DISEASE
WO2008136848A4 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
CA2999428C (en) Biomarkers for cervical cancer
JP2002517244A5 (en)
WO1995034650A3 (en) Mn gene and protein
JP2004500013A5 (en)
CA2450581A1 (en) Cardiovascular safety assay
CN115210386A (en) CRISPR-based assays for detecting TB in body fluids
JP2019531716A5 (en)
WO2004002296A3 (en) Therapeutic methods for reducing fat deposition and treating associated conditions
Efrati et al. LNA-based PCR clamping enrichment assay for the identification of KRAS mutations
JP2005507648A5 (en)
JP2005535289A5 (en)
JP2008507261A5 (en)
KR101670135B1 (en) DNA Aptamer Specifically Binding to LCN2 (Lipocalin 2) protein and Its Use
JP2021503289A (en) New CIP2A variant and its use
JP2004065264A5 (en)

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 14 AUG 2007

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 13 SEP 2007.

TH Corrigenda

Free format text: IN VOL 20, NO 33, PAGE(S) 3247 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME COMPUGEN USA, INC., APPLICATION NO. 2005320352, UNDER INID (43) CORRECT THE DATE TO 14.12.06

Free format text: IN VOL 20, NO 33, PAGE(S) 3225 UNDER THE HEADING APPLICATIONS OPI - NAME INDEX UNDER THE NAME COMPUGEN USA, INC., APPLICATION NO. 2005320352, UNDER INID (43) CORRECT THE DATE TO 14.12.06

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application